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Abstract
Background: Patients often express strong preferences for the forms of treatment available for their disease.
Incorporating these preferences into the process of treatment decision-making might improve patients’ adherence
to treatment, contributing to better outcomes. We describe the methodology used in a study aiming to assess
treatment outcomes when patients’ preferences for treatment are closely matched to recommended treatments.
Method: Participants included patients with moderate and severe psoriasis attending outpatient dermatology
clinics at the University Medical Centre Mannheim, University of Heidelberg, Germany. A self-administered online
survey used conjoint analysis to measure participants’ preferences for psoriasis treatment options at the initial study
visit. Physicians’ treatment recommendations were abstracted from each participant’s medical records. The
Preference Matching Index (PMI), a measure of concordance between the participant’s preferences for treatment
and the physician’s recommended treatment, was determined for each participant at t1 (initial study visit). A clinical
outcome measure, the Psoriasis Area and Severity Index, and two participant-derived outcomes assessing treatment
satisfaction and health related quality of life were employed at t1,t 2 (twelve weeks post-t1) and t3 (twelve weeks
post-t2). Change in outcomes was assessed using repeated measures analysis of variance. The association between
participants’ PMI scores at t1 and outcomes at t2 and t3 was evaluated using multivariate regressions analysis.
Discussion: We describe methods for capturing concordance between patients’ treatment preferences and
recommended treatment and for assessing its association with specific treatment outcomes. The methods are
intended to promote the incorporation of patients’ preferences in treatment decision-making, enhance treatment
satisfaction, and improve treatment effectiveness through greater adherence.
Keywords: Patients’ preferences, Patients’ satisfaction, Psoriasis, Psoriasis treatment
Background
Patient-centered care has been defined as being “respect-
ful of and responsive to individual patient preferences,
needs and values and ensuring that patient values guide
all clinical decisions” [1,2]. Patient-centered care fulfills
the obligation of healthcare providers to place the inter-
est of patients first and is associated with improved
patient satisfaction, quality of life and better treatment
adherence [1,3]. Although current debate exists around
the definition of patient-centered care, matching prefer-
ences for care with the treatment provided is thought to
be one of its key attributes [2,4].
Evidence supports the potential value of matching
patients’ preferences to treatment recommendations
[4,5]. For example, positive treatment outcomes such as
increased satisfaction with treatment and health-related
quality of life have been demonstrated when patient pre-
ferences for treatment attributes were incorporated into
treatment decision-making [5,6]. Matching patients’ pre-
ferences for involvement in treatment decision-making to
their actual level of involvement has also been associated
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any medium, provided the original work is properly cited.with greater satisfaction with care processes and reduced
levels of anxiety once treatment begins [5]. Insights from
these studies are somewhat limited, however, by the
methods used to elicit preferences. A simple binary
approach (i.e. stating a preference for treatment A over
treatment B), for example, fails to conform to traditional
health economic practices in which measurement of the
strength of patients’ preferences for a specific treatment
is thought to have greater meaning, and thus greater uti-
lity in decision-making. Moreover, the binary approach
described fails to reflect the trade-offs made with respect
to differing treatment attributes that may drive ultimate
treatment choice. In addition, a large number of studies
comparing patients’ versus physician treatment prefer-
ences use hypothetical scenarios, which provide few
insights into the real-world choices that patients actually
encounter [7].
Patients’ preferences for treatment have been shown to
affect patients’ treatment satisfaction [6,8]. Improvement
in treatment satisfaction has been associated with patients’
treatment adherence; patients’ treatment adherence is con-
sidered necessary for achieving optimal treatment out-
comes [8-11]. Thus, the conceptual model informing this
work suggest that the incorporation of patients’ treatment
preferences in treatment decision making may influence
patients’ clinical (i.e. disease severity) and Health Related
Quality of life (HRQoL) outcomes through greater satis-
faction and adherence with physician treatment recom-
mendations. Using a prospective cohort study design, our
methods aimed to test the hypothesis that a closer match
between physicians’ treatment recommendations and
patients’ treatment preferences may lead to reduction in
disease severity, less impairment in HRQoL, and improve-
ment in treatment satisfaction.
Tools that assess the strength of patients’ preferences for
treatment recommendations and potential trade-offs
among treatment attributes are needed. The availability of
such tools may enable more accurate assessment of the
effects of preference matching on treatment outcomes. In
this report, we describe the methods we used in a study
that assessed the association of preference matching with
objective clinical and participant-derived outcomes.
Methods
Setting
This study is being carried out in a bi-weekly outpatient
psoriasis clinic in the Department of Dermatology,
University Medical Centre Mannheim, University of
Heidelberg, a regional ‘Competence Centre for Psoriasis.’
The psoriasis clinic is a primary, secondary and tertiary
care referral centre, to which patients are referred by
family physician, general medical practitioners, general
internist, dermatologists and other community hospitals
from the Metropolitan Region Rheine-Necker. The clinic
therefore attends to population of patients with wide
spectrum of the disease. Approximately 250 to 300
patients with moderate to severe psoriasis attend these
clinics annually, making it a site at which it would be
feasible to recruit participants with a range of clinical
characteristics and disease severity.
Participants
Study participants were patients attending the outpatient
psoriasis clinic in the Department of Dermatology, Univer-
sity Medical Centre Mannheim. University of Heidelberg.
Inclusion criteria: participants were included if they were
18 years of age or older and were new or established
patients in the Department of Dermatology. Each had phy-
sician-diagnosed moderate or severe psoriasis according to
the criteria of the Committee for Medicinal Products for
Human Use [12], i.e., a Psoriasis Area and Severity Index
(PASI) ≥ 10, involvement of the head, the palmar or plan-
tar surfaces, or psoriatic arthritis with any skin involve-
ment and patients on systemic anti-psoriatic therapy.
These criteria were purposefully selected to ensure that
participants in the sample would require one or more
treatments from a broad range of available options. Exclu-
sion criteria: Participants were excluded if they were not
able to complete the online survey independently or if
they were unable to read and understand German (the
language in which the survey and subsequent interviews
were conducted).
Recruitment
To recruit a consecutive sample, each patient with moder-
ate or severe psoriasis attending dermatology outpatient
clinics was approached. Two members of the research
team were responsible for all aspects of recruitment,
including the distribution of informational leaflets about
the study, identification of potentially eligible participants,
assessment of eligibility (i.e., applying inclusion/exclusion
criteria) and obtaining informed consent. Once identified,
eligible participants were approached before their appoint-
ment with the physician and invited to participate in the
study. Informed consent was then obtained, a unique
four-digit study identification number was assigned and
the two study follow-up visits were scheduled (t2 (twelve
weeks post-t1)a n dt 3 (twelve weeks post-t2)). After com-
pleting an online survey (described below), participants
proceeded to their medical appointment. Steps in recruit-
ment and data collection are summarized in Table 1.
Data elements
The primary independent variable was the Preferences
Matching Index (PMI), a measure of concordance devel-
oped in three steps: Step 1 involved the elicitation of
participants’ preferences for available treatment options
in terms of their “attributes” (i.e., processes or potential
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“levels” or “categories” (i.e., the possible forms a treat-
ment might take). In Step 2, physicians’ treatment
recommendations were abstracted from participants’
medical records. Step 3 entailed the calculation of the
PMI using a process of conjoint analysis to quantify
concordance between participants’ treatment preferences
and the treatment recommended at the initial study visit
at (t1) by the physician. The PMI was determined only
at t1 (initial study visit). Each step is described below in
detail.
Elicitation of patients’ preferences (Step 1)
‘Patients’ preferences’ here refers to the value patients
attach to different treatment attributes when faced with
treatment options. A range of potentially appropriate
and currently available psoriasis treatments modalities
were identified by using the ‘German evidence-based
guidelines for the treatment of psoriasis’ [14] and by
consultations with clinical experts (AS and WP). Process
and outcomes of currently available treatments were
decomposed into attributes and attribute levels or cate-
gories. This process was guided by review of studies that
assessed preferences for psoriasis treatments [5,6,15].
Four attribute levels or categories were specified for
each treatment attribute (Table 2) [13]. Although a large
number of attribute levels could have been developed, we
decided to limit confine the number to four categories to
limit respondent burden and avoid information overload.
We further refined attribute categories for clarity of con-
tent using comments from the participants, following a
pilot of the conjoint analysis exercise described below.
Treatment attributes and attribute categories were
labeled to distinguish elements of the process of treat-
ment from those resulting from the care (outcomes).
Examples of process attributes included the ‘delivery
method’ (mode of drug administration) or ‘location of
treatment’. An example of attribute categories for the
process-related treatment attribute ‘location of treatment’
included: ‘treatment at home’, ‘treatment at the local doc-
tor’so f f i c e ’, ‘treatment at an outpatient clinic’, and ‘treat-
ment at an inpatient clinic’. Examples of outcome
attributes included the ‘severity of potential side effects’,
‘possibility of beneficial effect’ and ‘reversibility of side
effects’ that may result from a particular psoriasis treat-
ment modality. A full list of attributes and attribute cate-
gories is provided in Table 2 [13].
We used ‘choice-based conjoint analysis’ (CBC) to mea-
sure participants’ preferences for specific psoriasis treat-
ments. This method best simulates the way people make
everyday choices when faced with multiple options [16]
and has the additional advantages of being previously vali-
dated, easy to use, and efficient in assessing patients’ pre-
ferences for health care and their treatment priorities [16].
To conduct our analysis, we used survey design software
Table 1 Steps involved in participants’ recruitment and data collection
Recruitment/
Data collection steps
Activities
1. Participant recruitment Participants were approached at the outpatient clinic while waiting for their doctor’s appointment. The
setting was considered convenient for recruitment as it provided access to relatively large numbers of
potential participants who fit the study’s inclusion criteria. Further, since patients have to wait for their
doctor’s appointment at the outpatient clinic, asking participants to answer the survey during this
waiting period was not viewed as imposing an undue burden on their time.
2. Informed consent Patients who agreed to participate completed and returned a signed informed consent form.
3. Allocation of study identification
number/initial screening
Participants who returned the signed consent forms and were considered eligible were assigned study
identification numbers for anonymity. Appointment dates were also set for subsequent follow-up visits.
4. Administration of the survey Participants’ were guided to the room and computer where they completed the survey.
5. Doctor’s appointment After completing the survey, participants were directed to their respective doctor’s appointment.
6. Data abstraction and forwarding Participants’ PASI scores and doctor’s treatment recommendation were abstracted from the medical
records and faxed to the study coordination center at the Mannheim Institute of Public Health (MIPH)
for entry into a database.
7. Participant screening Inclusion and exclusion criteria were further applied at this stage, using the abstracted data, to screen
participants for eligibility.
8. Non-eligible patients Participants considered non-eligible were not followed for subsequent study visits and their records
were deleted.
9. Eligible patients Eligible patients were followed for subsequent study visits and their records were stored according to
data protection laws.
10. t1 (initial study visit) Initial study visit data was collected.
11. t2 (12 weeks after t1) First follow-up visit data was collected.
12. t3 (12 weeks after t2) Second follow-up visit data was collected.
13. Study coordination and data storage at
MIPH
The survey data forwarded from the study site (dermatology department) was securely stored at the
MIPH.
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Page 3 of 10(Sawtooth, Inc., Sequim, WA) to present participants with
twelve pair-wise comparisons comprised of random com-
binations (see Table 3) [13] of the profiled attribute cate-
gories (twelve random combinations of attribute
categories per pair). In a final analytical step, “preference
scores” (partworth utilities values) were generated for
every participant for each attribute level or category of
psoriasis treatment option, with higher scores indicating a
Table 2 Profile of treatment attributes and attribute levels
Treatment Attribute Attribute Levels (categories)
Treatment duration
a Each treatment will take:
￿ 5 minutes to complete.
￿ 15 to 30 minutes to complete.
￿ 1 hour to complete.
￿ 2 hours to complete.
Treatment frequency
a My treatment will occur:
￿ Once every three months.
￿ Once every two weeks.
￿ Two times each week.
￿ Twice daily.
Treatment cost
a I will have to pay:
￿ Nothing to cover the cost of my treatments.
￿ An additional 50 € per month to cover the cost of my treatments.
￿ An additional 100 € per month to cover the cost of my treatments.
￿ An additional 200 € per month to cover the cost of my treatments.
Treatment location
a My treatment will take place:
￿ At home.
￿ At home with follow-up at my local doctor’s office.
￿ At an outpatient clinic.
￿ While I stay in the hospital for three weeks.
Treatment delivery method
a My treatment will occur by:
￿ Applying medication on my skin.
￿ Taking Tablets.
￿ Having an injection/intravenous infusion.
￿ Light therapy.
Magnitude of beneficial effect
b I will likely experience:
￿ Almost a 100% reduction in my psoriasis plaques.
￿ About a 75% reduction in my psoriasis plaques.
￿ About a 50% reduction in my psoriasis plaques.
￿ About a 25% reduction in my psoriasis plaques.
Duration of beneficial effect
b The improvement in my psoriasis will last for:
￿ 1 year or more after completing all of my treatments.
￿ 6 to 8 months after completing all of my treatments.
￿ 3 to 5 months after completing all of my treatments.
￿ 2 weeks after completing all of my treatments.
Probability of side effects
b There is:
￿ Almost a 100% chance that I will experience side effects from the treatment.
￿ About a 50% chance that I will experience side effects from the treatment.
￿ About a 10% chance that I will experience side effects from the treatment.
￿ Less than 1% chance that I will experience side effects from the treatment.
Probability of beneficial effect
b I have:
￿ Almost a 100% chance of experiencing a significant reduction in my psoriasis.
￿ About an 80% chance of experiencing a significant reduction in my psoriasis.
￿ About a 60% chance of experiencing a significant reduction in my psoriasis.
￿ About a 40% chance of experiencing a significant reduction in my psoriasis.
Reversibility of side effects
b If side effects occur, there is:
￿ Almost 100% chance that I will completely recover once my treatments are stopped.
￿ About an 80% chance that I will completely recover once my treatments are stopped.
￿ About a 60% chance that I will completely recover once my treatments are stopped.
￿ About a 40% chance that I will completely recover once my treatments are stopped.
Side effect severity
b I may experience:
￿ Temporary, minor discomfort on my skin.
￿ Constant, moderate discomfort on my skin.
￿ Temporary, moderate side effects that can effect more than my skin.
￿ Severe side effects that can effect more than my skin.
Note: (
a) = Process attributes and levels; (
b) = Outcome attributes and levels
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though a subset of potential treatments were randomly
selected and presented to the participant, the software
algorithm (using an orthogonal design) is programmed to
extrapolate preference values for all possible treatments
and treatment levels for each study participant.
Abstraction of physician-recommended treatments (Step 2)
A member of the research team (MS) trained in the inter-
pretation of data documented in medical records was
responsible for abstracting data on the actual treatment
modalities recommended by physicians for each partici-
pant. Participants’ medical records were retrieved after
their clinical visit at t1 and data were abstracted using a
standardized data collection form and entered into a data-
base. Accuracy of data entry was confirmed by review at
each subsequent study visit of all previously recorded data.
In the event of multiple treatment recommendations at t1,
all were recorded.
Determining the level of concordance (Step 3)
First we identify participants’-preferred treatments and
most preferred attribute categories with the highest scores;
we also identified participants’ least preferred treatment
and least preferred attribute categories with the lowest
scores from the conjoint analysis described above. The
same process was followed for identifying the scores asso-
ciated with the physician-recommended treatments, and
their associated attributes, for each participant.
To illustrate, if Table 4 represents preference scores from
a conjoint analysis for a hypothetical participant presented
with three randomly selected treatment attributes, the par-
ticipant appears to most prefer light therapy treatment
(preference score = 44) at an outpatient clinic (preference
score = 19) lasting between 15-30 minutes (preference
score = 27). If the treatment recommended by the physi-
cian for this participant was ‘methotrexate tablets’,t h e
attribute categories ascribed to this treatment would be:
“tablets”, “taken at home” and “5 minutes” for anticipated
treatment type, location, and anticipated duration, respec-
tively. These attribute categories correspond to participant-
derived preference scores of 10, 17 and 23 (Table 4).
Next, scores for treatment attribute categories most
preferred by the participants (attribute categories with
the highest preferences score) and attribute categories
least preferred by the participants (attribute categories
with lowest preference scores) were summed. Further,
scores for physician recommended treatment were
Table 3 Example of treatment scenarios presented to the study participants in the conjoint analysis survey
Imagine that you will be actively treating your psoriasis for the next three months. From each pair of treatment options A and B, please
pick which treatment you will like to participate in.
Option A
My treatments will take place at home.
My treatments will occur twice daily.
Each treatment will take one hour to complete.
Option B
My treatments will take place while I stay in the hospital for three
weeks.
My treatment will occur once every three months.
Each treatment will take 15 to 30 minutes to complete.
I may experience constant, moderate side effects that can affect more
than my skin.
I may experience constant, minor discomfort on
my skin.
I have about an 80% chance of experiencing a significant reduction in
my psoriasis plaques.
I have almost a 100% chance of experiencing a significant reduction in
my psoriasis plaques.
The improvement in my psoriasis will last for 3 to 5 months after
completing all of my treatments.
The improvement in my psoriasis will last for 3 to 5 months after
completing all of my treatments.
Table 4 Example of preferences scores (partworth utilities) for treatment attributes and attribute levels for a
hypothetical respondent
Treatment attributes Attribute categories Preference score (utilities)
Attribute 1. Treatment delivery method Category 1. Topical -74
Category 2. Tablets 10
Category 3. Injection/infusion 20
Category 4. Light therapy 44
Attribute 2. Treatment location Category 1. At home 17
Category 2. At local doctor’s office 2
Category 3. At outpatient clinic 19
Category 4. Hospital stay -34
Attribute 3. Treatment duration Category 1. 5 minutes to complete 23
Category 2. 15-30 minutes to complete 27
Category 3. 1 hour to complete -26
Category 4. 2 hours to complete -24
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our hypothetical participants’ most preferred treatment
and least preferred treatment in the example above is 90
(= 44+19+27) and -134 (= -74-34-26) respectively, while
the sum of preference scores for the physician-recom-
mended psoriasis treatment is 50 (= 10+17+23).
We then constructed a scale with two end points: the
participants’ most preferred treatment and the partici-
pants’ least preferred treatment (Figure 1). To determine
the PMI, the range between the preference scores for
recommended treatment and the least preferred treat-
ment was divided by the range between the most pre-
ferred treatments and the least preferred treatment or
b/c (Figure 1). In the example, the PMI is therefore [50-
(-134)/90-(-134)], representing the concordance between
the preference scores for the physician treatment recom-
mendations and preference scores for the participants’
preferred treatment. The PMI ranges between 0 (no pre-
ference concordance) and 1 (complete preference con-
cordance). To ensure data quality and the accuracy of the
PMI computed, we repeated calculations at each stage. In
the rare instances in which discrepancies were found, we
returned to the original data to confirm and re-enter
values.
The dependent variables in our analysis consisted of
both objective clinical and participant-derived outcome
measures (Table 5). The dependent variables were
assessed t1,t 2 (twelve weeks post-t1) and t3 (twelve weeks
post-t2). Twelve weeks are known to be sufficient to judge
the short-term effectiveness of a psoriasis treatment, but
we specifically wanted to look at longer-term outcomes at
24 weeks which may better represent sustainable treat-
ment adherence [17]. Our analyses therefore focused on
changes observed between t1 and t3, although additional
analyses (not described here) were also performed for
changes observed between t1 and t2.
The primary dependent variable was the change in
PASI score from t1 to t3. The PASI is a psychometrically
valid and reliable instrument routinely applied in derma-
tology to assess psoriasis se v e r i t ya n dg a u g et r e a t m e n t
effects [17]. PASI combines assessment of the severity of
psoriasis lesions and the area affected into a score ran-
ging from 0 (no disease) to 72 (maximal disease), with
scores ≥ 10 reflecting moderate to severe disease [17].
The secondary dependent variables included change
in patients’ satisfaction with treatment from t1 to t3
measured by the Treatment Satisfaction Questionnaire
for Medication (TSQM) and change in self-reported
health-related quality of life (HRQL) from t1 to t3 mea-
sured by the Dermatology Quality of Life Index (DLQI).
TSQM is a 14-item, psychometrically validated instru-
ment [18]. The DLQI, a validated questionnaire, is one
of the most widely used instruments to assess the
health-related quality of life of patients with skin condi-
tions. DLQI scores range from 0 to 30, with higher
scores indicating greater impairment in skin disease-spe-
cific quality of life [19].
We identified potential confounding characteristics
including sex (male, female); age (measured in years);
partnership status (i.e., living with a partner, not living
with a partner, widowed); employment status (i.e., full-
time, part-time, not working), highest educational attain-
ment (i.e., no school, primary school equivalent, second-
ary school equivalent, post-secondary school training,
university, post-university) and net annual household
income (measured in Euros) [20,21]. Based on previous
work, we measured a number of factors that might
moderate participants’ satisfaction and compliance with
treatment, including treatment history (i.e., previously
prescribed treatments) and disease-related factors (i.e.,
time since diagnosis and co-morbidities [e.g. depression:
yes/no]) [21].
Data sources/data collection
As previously mentioned, data were obtained from two
sources: participants’ survey responses and physicians’
notations in their medical records (Table 5). The survey,
developed using ‘Sawtooth Survey Software for Online
Interviewing’ (Sawtooth, Inc., Sequim, WA), was adminis-
tered in the dermatology clinic using either a desktop
computer or laptop located in a separate room away from
the waiting area. A member of the research team was
available to demonstrate how the survey instrument func-
tioned. Data collected via the online survey was stored in a
secure server and accessed for analysis via the Internet.
Analytic strategy
Design
We utilized a prospective cohort study design to assess
the association of the concordance between patients’
preferences to physician-recommended treatments with
subsequent treatment outcomes.
Sample size
To detect a moderate-sized change in our primary out-
come measure between t1 and t3, we set an effect size (f
2)
of 0.15 [12], a =0 . 0 5a n db =0 . 2 0 .U s i n gt h e s ep a r a -
meters, we estimated that a minimum sample size of 200
was needed. Adjusting for a possible dropout rate of 20%
Most 
preferred 
treatment 
Least 
preferred 
treatment 
Recommended 
treatment 
 

Figure 1 Illustration of the scaling used to determine the
Preference Matching Index.
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required sample size to 240 patients. We considered this
recruitment goal to be attainable given the annual patient
volume at the study site.
Specific aims, tasks and hypotheses
Our methods aimed to address the following:
￿ To develop the Preference Matching Index (PMI)
as a novel metric that assesses the concordance
between a physician’s treatment recommendation
and a participants’ most preferred treatment.
￿ To evaluate the association between PMI scores
and change in PASI over time.
Hypothesis: There will be a statistically significant
negative association between participants’ PMI and
absolute change in PASI between t1 and t3.
￿ To evaluate the association between participants’
PMI scores and non-clinical outcomes including
change in satisfaction with treatment and Health
Related Quality of Life (HRQL).
Hypotheses: There will be a statistically significant
positive association between PMI and absolute
Table 5 Variables, measurement instruments and data sources
Variable Measurement Instrument Data Source Data Collection
Period
Independent Variable
PMI Conjoint analysis survey/Doctors’
recommendations
Participants t1
PMI Doctors’ recommendations Participants’ medical
records
t1,t 2,t 3
Dependent Variable
PASI scores Physician-assessed PASI [17] Participants’ medical
records
t1,t 2,t 3
TSQM scores Self-reported TSQM questionnaire [18] Participants t1,t 2,t 3
DLQI scores Self-reported DLQI questionnaire [19] Participants t1,t 2,t 3
Confounders
Demographic factors Standard German demographic
questionnaire
Participants t1
Sex
Age
Partnership
Living with a partner/living alone
Education
Highest educational attainment
Income
Net monthly household income
Number of household members
Employment status
Full-time
Part-time
Not working
Treatment factors Self-reported questionnaire Participants t1
Currently receiving psoriasis treatment or not
Type of psoriasis treatment (topical, UV therapy, Tablets,
injections/infusions)
Disease-related factors Self-reported questionnaire Participants t1
Time since diagnosis
Co-morbidities
Psoriatic arthritis
Depression
Allergy
High blood pressure
Cardiovascular disease
Hyperlipidemia
Chronic lung disease, asthma
Liver disease
Diabetes
Cancer
Note: DLQI = Dermatology Quality of Life Index; PASI = Psoriasis Area and Severity Index; TSQM = Treatment Satisfaction Questionnaire for Medication;t 1 = initial
study visit; t2 = first follow-up study visit twelve weeks after t1;t 3 = second follow-up study visit twelve weeks after t2
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between t1 and t3.
Hypotheses: There will be statistically significant nega-
tive associations between participants’ PMI and abso-
lute change in change in HRQL between t1 and t3.
Statistical analysis
Baseline data will be used to identify factors associated
with participants’ preferences and treatment satisfaction,
HRQoL and disease severity in the study sample. Data of
participants’ lost to follow-up will examine the characteris-
tics associated with dropout. Change in outcome measures
across the three data collection points will be assessed
using repeated measure analysis of variance. The relation-
ship between participants’ PMI scores and each of the
three study outcomes will be evaluated using separate
multivariate linear regressions models: the association of
PMI with the objective clinical outcome (model 1) and the
association of PMI with patient reported treatment satis-
faction (model 2) and HRQL (model 3), controlling for
known confounders (e.g. age, education, marital status and
income) [22]. In sensitivity analysis, we will stratify our
analysis by gender, and by new and established (old)
patients; treatment experience (new or old) may affect
patients’ treatment preferences) [23].
Ethical and human subjects’ confidentiality
The ethics committee of the Medical Faculty Mannheim,
University of Heidelberg granted approval for the study
(ID 2009-329E-MA). The methodology used in this study
followed the principles of the Helsinki Declaration. Statis-
tical analyses were performed using either Sawtooth soft-
ware (Sawtooth, Inc., Sequim, WA) or SPSS statistical
package version 19 (Chicago, IL).
Discussion
In this paper, we describe the methods used to develop
a measure of the concordance between patients’ prefer-
ences for treatment and actual treatment recommenda-
tions. We also detail the methods used to assess the
association of this measure with both objective clinical
and patient-derived outcomes.
Substantial effort has been devoted to creating a health
care environment in which the needs and preferences of
patients are both acknowledged and incorporated into
decision-making. Unfortunately, the tools available to
support this effort are limited in both quantity and qual-
ity. Ideally these tools should be capable of assessing a
broad spectrum of available medical interventions (i.e.,
the processes of care) and realistic outcomes of care.
Conjoint analysis best simulates the way people make
everyday choices when faced with multiple options and
can help identify treatment features that drive patients’
treatment preferences (9). Further, conjoint analysis has
the additional advantages of being validated, easy to use,
and increasingly recognized as an efficient way to assess
patients’ preferences for health care and their treatment
priorities [16]. In addition, in routine clinical practice or
research, the preference scores derived from the conjoint
exercises can be compared with treatment recommenda-
tions from physicians to determine the extent of prefer-
ence matching and sharing [16].
T h em e t h o d sw ed e s c r i b em a yb ea p p l i e dt od e c i s i o n -
making for the management of other chronic diseases.
Although such applications requires an initial investment
of time and expertise in revision of the conjoint analysis
survey, the introduction of new treatments (attributes and
attribute levels) can be subsequently added with relative
ease to data previously stored by the program. Our work
uses psoriasis as an example of a common chronic disease,
yet we fully expect that this methodology may be useful in
promoting shared decision-making in the management of
other diseases.
Mismatch between physicians’ and patients’ treatment
preferences have been reported [24]. Mismatch between
physicians’ and patients’ treatment preferences may results
in patients receiving treatment they are dissatisfied with,
which may affect their adherence to the recommended
treatments [24]. Understanding the association of prefer-
ence matching (captured by the PMI) with treatment out-
comes may provide important insight on the potential
value of using psoriasis patients’ preferences in shared
decision-making.
Based on the preference scores elicited from the conjoint
analysis, it is possible for a patient to have equal or near
equal preference for two different treatment options [25],
if the two treatment options share certain attributes the
patient value equally (e.g. a tablet and a cream can both be
taken at home and their administration may take less
time). This has important implication in treatment deci-
sion; it gives room for a more meaningful shared decision-
making to happen. Physicians can acknowledge patients
preferences, and still have the freedom to trade between
different treatment attributes and attribute levels when
making treatment recommendations.
Despite the strength of the methods we have described,
a number of limitations should be acknowledged. Partici-
pants may, for example, report biased preferences when
completing the conjoint exercise due to a ‘dominant pre-
ference’ for a particular attribute. That is, they may refuse
to trade between treatment attribute categories because of
strong feelings about the perceived nature of some treat-
ments. Second, we have not measured adherence directly.
The conceptual model informing this work suggests, how-
ever, that satisfied patients are more likely to adhere to
recommended treatments and that this explains, to some
extent, the presence of more desirable outcomes. Finally,
some have suggested that the process of preference elicita-
tion may influence subsequent reporting of treatment
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against this, we assessed preferences before consultation
and did not share these results with patients at any point
during the study.
Conclusion
We describe a novel method for measuring concordance
between patients’ most preferred treatments and physi-
cians’ recommended treatments and for assessing the
association of concordance with treatment outcomes. Tai-
loring treatment recommendations to patients’ preferences
is an essential part of patient-centered care. Efforts to
implement preference-based tailoring in routine clinical
care may improve the quality of the interaction between
patients and physicians, patients’ adherence with treat-
ment, satisfaction with treatment and clinical outcomes
achieved. The methods reported here, although originally
tested within the context of psoriasis treatment, have the
potential to advance greater patient-centeredness in the
management of other chronic diseases.
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